Every AI newsletter, investors ask questions on the investor interaction platform: winter is the season of high incidence of influenza. Does the company have any new innovations in children’s medication? Are there targeted and effective drugs for viral pneumonia in children? Does the national centralized purchase of traditional Chinese medicine affect the company? Has the company won the bid?
Sunflower Pharmaceutical Group Co.Ltd(002737) (002737. SZ) said on the investor interaction platform on January 14 that children’s medicine has always been the company’s core strategy, and the company will continue to strengthen the research and development of children’s medicine. At present, the OTC side of the company’s business accounts for a large proportion, and centralized purchase has not had a significant impact on the company’s operation.
